Olympus (TYO:7733) today announced that it has completed the separation of its Scientific Solutions division into a wholly owned subsidiary called Evident.
The creation of Evident – which encompasses life science research and industrial equipment – enables Olympus management to better focus on the continued growth of the company’s medical business, which accounted for 86% of turnover for the 2020-2021 financial year.
Based in Japan, Evident will operate independently under the Olympus umbrella. Olympus said the new Evident name exemplifies a commitment to delivering high-quality products and technical expertise – and a renewed focus on working with customers and being responsive to customer concerns.
“Evident, while continuing to provide best-in-class products, will expand its digital and cloud-based solutions to enhance customer experience and improve overall workflow in the research and inspection fields,” said Yoshitake Saito, President and Representative. director of Evidence.
“We will move from a business model focused on selling products to one focused on solving customer problems and challenges. With this greater management autonomy, we will promote agile product development and open innovation, which we believe will accelerate the speed of product development.